<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04339868</url>
  </required_header>
  <id_info>
    <org_study_id>Si 049/2020</org_study_id>
    <nct_id>NCT04339868</nct_id>
  </id_info>
  <brief_title>Terlipressin for Refractory Septic Shock</brief_title>
  <acronym>TERESEP</acronym>
  <official_title>Terlipressin Versus Placebo for Septic Shock Refractory to High Doses Catecholamine Vasopressors: A Randomized-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Norepinephrine was recommended as the first vasopressor for septic shock resuscitation.

      For the patient who did not response to high dose norepinephrine, epinephrine was
      recommended.

      Vasopressin was also recommended as an alternative vasopressor, in case patient did not
      response to norepinephrine and or epinephrine.

      Terlipressin, a selective V1 receptor binding with long half life, was reported that it main
      action is to increase blood pressure via the different mechanism from norepinephrine and
      epinephrine.

      To use terlipressin, combine with norepinephrine and or epinephrine among refractory septic
      shock, could decrease the usage dose of norepinephrine and epinephrine as well as lower the
      side effects of too high adrenergic stimuli.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Norepinephrine was recommended as the first vasopressor for septic shock resuscitation.

      For the patient who did not response to high dose norepinephrine, epinephrine was
      recommended.

      Both norepinephrine and epinephrine action via the alpha adrenergic stimuli to increase
      vascular smooth muscle contraction, induced vasoconstriction and increase arterial blood
      pressure. It also action via beta adrenergic stimuli, to increase heart rate and myocardial
      contractility, then increase stroke volume and cardiac output.

      Too much alpha and beta adrenergic stimulation, especially during received high dose
      norepinephrine and or epinephrine associated with vasoconstriction induce organs ischemia.

      The most common organ ischemia included myocardial ischemia, bowel ischemia and limbs
      ischemia.

      Cardiac arrhythmia was also the most common complication associated with high dose
      norepinephrine and or epinephrine.

      Atrial fibrillation was the most common reported arrhythmia, however, fatal arrhythmia
      included ventricular fibrillation and tachycardia were also reported.

      Vasopressin was recommended as an alternative vasopressor, in case patient did not response
      to norepinephrine and or epinephrine.

      Terlipressin, a selective V1 receptor binding with long half life, was reported that it main
      action is to increase blood pressure via the different mechanism from norepinephrine and
      epinephrine.

      To use terlipressin, combine with norepinephrine and or epinephrine among refractory septic
      shock, could decrease the usage dose of norepinephrine and epinephrine as well as lower the
      side effects of too high adrenergic stimuli.

      The benefit effect of terlipressin could be demonstrated when prescribe among the septic
      shock patients who required high dose of adrenergic vasoactive agents.

      Terlipressin plus norepinephrine and or epinephrine could maintain or even improve blood
      pressure and tissue perfusion with lower fatal side effects than norepinephrine and or
      epinephrine without terlipressin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention arm: Terlipressin plus Norepinephrine and/or Epinephrine Controlled arm: Placebo plus Norepinephrine and/or Epinephrine for Treatment Refractory Septic Shock</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Performed a randomization table before enrollment. Prepare the study drug receiving or placebo receiving according to sequential number derived from the randomization table and keep it in a conceal envelop. Prepare study drug and placebo by a pharmacist or an investigation nurse, according to the randomization table number, and keep both study drug and placebo in the identical containment which labeled by a sequential number. Once a patient was enrolled and informed was signed, then study drug or placebo was start according to sequential number.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Achieve target blood pressure with low dose adrenergic agents</measure>
    <time_frame>6 hours after initiate study drug</time_frame>
    <description>Achieve target mean arterial blood pressure 65 millimeter mercury or more with norepinephrine and/or epinephrine dose 0.2 mcg/kg/min or lower</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of patient who dead before 28 days after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial blood pressure</measure>
    <time_frame>72 hours</time_frame>
    <description>Mean arterial blood pressure after initiate study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patient who dead before hospital discharge after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patient who dead before ICU discharge after enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Septic Shock</condition>
  <condition>Refractory Shock</condition>
  <condition>Norepinephrine Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Terlipressin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Terlipressin acetate 1 mg in 0.9% normal saline (NaCl) 50 mL (0.02 mg/mL) Initial dose 20 mcg/hr (1 mL/hr) titrate increase 1 mL/hr every 30 min to 100 mcg/hr (5 mg/hr) to keep mean arterial blood pressure (MAP) &gt; 65 mmHg If MAP &gt; 75 mmHg for &gt; 30 min, decrease epinephrine and norepinephrine until &lt; 0.15 mcg/kg/min, then decrease terlipressin until stop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 0.9% NaCl 50 mL Initial dose 1 mL/hr titrate increase 1 mL/hr every 30 min to 5 mg/hr to keep mean arterial blood pressure (MAP) &gt; 65 mmHg If MAP &gt; 75 mmHg for &gt; 30 min, decrease epinephrine and norepinephrine until &lt; 0.15 mcg/kg/min, then decrease placebo until stop</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine</description>
    <arm_group_label>Terlipressin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% NaCl plus norepinephrine and/or epinephrine</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Septic shock according to Sepsis-3 definition

          -  Evidence of adequate fluid

          -  Received norepinephrine 0.2 mcg/kg/min or more

          -  Received norepinephrine plus epinephrine (any dose)

          -  Mean arterial lower than 65 mmHg or lactate &gt; 2 mmol/liter

        Exclusion Criteria:

          1. Septic shock diagnosis &gt; 48 hours before

          2. Receive intravenous fluid &lt; 30 mL/kg before enrollment

          3. Do-not-resuscitation and terminally ill

          4. Refractory to treatment malignancy

          5. Pregnancy

        7. Chronic renal failure stage 5 with no plan for long term renal replacement therapy 8.
        Cirrhosis child C 9. Cardiogenic shock 10. Acute decompensated heart failure 11. Evidence
        of left ventricular ejection fraction (LVEF) &lt; 35% 12. Acute coronary syndrome within 72
        hours 13. Severe valvular heart disease 14. Documented life-threatening tachyarrhythmia
        before enrollment 15. Diagnosis of acute mesenteric ischemia before enrollment 16. Previous
        diagnosis of Raynaud's phenomenon 17. Known peripheral arterial disease 18. Refuse to sign
        the informed consent by patient or representative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Surat Tongyoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Surat Tongyoo, MD</last_name>
    <phone>0820137771</phone>
    <email>surat.ton@mahidol.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chawanee Chayakul, MD</last_name>
    <phone>080-440-1137</phone>
    <email>jingjaring@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Surat Tongyoo, MD</last_name>
      <phone>6624198534</phone>
      <email>surat.ton@mahidol.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Chawanee Chayakul, MD</last_name>
      <phone>080-440-1137</phone>
      <email>jingjaring@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tanuwong Vialasilpa, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chawanee Chayakul, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chairat Permpikul, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18.</citation>
    <PMID>28101605</PMID>
  </results_reference>
  <results_reference>
    <citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</citation>
    <PMID>26903338</PMID>
  </results_reference>
  <results_reference>
    <citation>Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S. Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial. Am J Respir Crit Care Med. 2019 May 1;199(9):1097-1105. doi: 10.1164/rccm.201806-1034OC.</citation>
    <PMID>30704260</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data set and analysis are available from the corresponding author on reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After complete enrollment and for 24 months</ipd_time_frame>
    <ipd_access_criteria>Please direct contact to the principle investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

